Piramal Pharma Solutions (PPS), a CDMO based in India and part of Piramal Pharma, reports that it plans to invest $80 million to expand its Lexington, KY facility. The site, which specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products, plays an important vital role in Piramal Pharma Solutions integrated antibody-drug conjugate development and manufacturing program, ADCelerate™.
The investment aims to enhance the site’s existing capacity and capabilities. The expansion will equip the Lexington site with an additional 24,000 ft2 of manufacturing space, a new laboratory, and advanced machinery to scale clients’ products.
Additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. Currently, the Lexington site can manufacture 104 product batches per year (utilization at peak levels). Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches, according to Nandini Piramal, chairperson, Piramal Pharma.
“This expansion represents a strategic investment in the future of Piramal Pharma. Filling the commercial manufacturing gap enables the Lexington site to access the rapidly expanding injectables market and establish itself as a key player in the segment,” said Piramal, pointing out that significant research, development, and scientific innovation have driven rapid growth in the injectables market, with an expected market value exceeding $20B by 2028.
As the efficiency and efficacy of injectable treatment options improve, more patients will benefit from these advanced therapies, she noted.
“The injectables market has steadily increased in recent years and there is currently insufficient supply. We are committed to adapting to meet this rising demand,” added Peter DeYoung, CEO, Piramal Global Pharma. “This expansion will significantly enhance the capacity and capabilities of our Lexington facility, positioning Piramal Pharma as a comprehensive partner across the entire product life cycle and enabling us to provide treatment solutions to more patients.”
